
After many external research results with GLP-1 drugs used to treat Alzheimer's disease have been publicly presented, Novo Nordisk has opted to initiate its own research program, which the pharmaceutical company states on Wednesday afternoon in a company announcement.
Novo Nordisk expects to recruit around 3,700 patients with early-stage Alzheimer's, who will test the semaglutide treatment, which is advertised as a treatment for diabetes in either tablet form or in the form of injections.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app